Skip to main content

Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations.

Publication ,  Journal Article
Weinstock, JS; Chaudhry, SA; Ioannou, M; Viskadourou, M; Reventun, P; Jakubek, YA; Liggett, LA; Laurie, C; Broome, JG; Khan, A; Taylor, KD ...
Published in: Nat Commun
October 16, 2025

Clonal hematopoiesis (CH) is defined by the expansion of a lineage of genetically identical cells in blood. Genetic lesions that confer a fitness advantage, such as leukemogenic point mutations or mosaic chromosomal alterations (mCAs), are frequent mediators of CH. However, recent analyses of both single cell-derived colonies of hematopoietic cells and population sequencing cohorts have revealed CH frequently occurs in the absence of known driver genetic lesions. To characterize CH without known driver genetic lesions, we use 51,399 deeply sequenced whole genomes from the NHLBI TOPMed sequencing initiative to perform simultaneous germline and somatic mutation analyses among individuals without leukemogenic point mutations (LPM), which we term CH-LPMneg. We quantify CH by estimating the total mutation burden. Because estimating somatic mutation burden without a paired-tissue sample is challenging, we develop a novel statistical method, the Genomic and Epigenomic informed Mutation (GEM) rate, that uses external genomic and epigenomic data sources to distinguish artifactual signals from true somatic mutations. We perform a genome-wide association study of GEM to discover the germline determinants of CH-LPMneg. We identify seven genes associated with CH-LPMneg (TCL1A, TERT, SMC4, NRIP1, PRDM16, MSRA, SCARB1).Functional analyses of SMC4 and NRIP1 implicated altered hematopoietic stem cell self-renewal and proliferation as the primary mediator of mutation burden in blood. We then perform comprehensive multi-tissue transcriptomic analyses, finding that the expression levels of 404 genes are associated with GEM. Finally, we perform phenotypic association meta-analyses across four cohorts, finding that GEM is associated with increased white blood cell count, but is not significantly associated with incident stroke or coronary disease events. Overall, we develop GEM for quantifying mutation burden from WGS and use GEM to discover the genetic, genomic, and phenotypic correlates of CH-LPMneg.

Duke Scholars

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

October 16, 2025

Volume

16

Issue

1

Start / End Page

9194

Location

England

Related Subject Headings

  • Point Mutation
  • Humans
  • Germ-Line Mutation
  • Genomics
  • Genome-Wide Association Study
  • Clonal Hematopoiesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weinstock, J. S., Chaudhry, S. A., Ioannou, M., Viskadourou, M., Reventun, P., Jakubek, Y. A., … Arvanitis, M. (2025). Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations. Nat Commun, 16(1), 9194. https://doi.org/10.1038/s41467-025-64236-x
Weinstock, Joshua S., Sharjeel A. Chaudhry, Maria Ioannou, Maria Viskadourou, Paula Reventun, Yasminka A. Jakubek, L Alexander Liggett, et al. “Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations.Nat Commun 16, no. 1 (October 16, 2025): 9194. https://doi.org/10.1038/s41467-025-64236-x.
Weinstock JS, Chaudhry SA, Ioannou M, Viskadourou M, Reventun P, Jakubek YA, et al. Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations. Nat Commun. 2025 Oct 16;16(1):9194.
Weinstock, Joshua S., et al. “Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations.Nat Commun, vol. 16, no. 1, Oct. 2025, p. 9194. Pubmed, doi:10.1038/s41467-025-64236-x.
Weinstock JS, Chaudhry SA, Ioannou M, Viskadourou M, Reventun P, Jakubek YA, Liggett LA, Laurie C, Broome JG, Khan A, Taylor KD, Guo X, Peyser PA, Boerwinkle E, Chami N, Kenny EE, Loos RJ, Psaty BM, Tracy RP, Brody JA, Yun JH, Cho MH, Vasan RS, Kardia SL, Smith JA, Raffield LM, Bidulescu A, O’Brien EC, de Andrade M, Rotter JI, Rich SS, Chen YDI, Gu CC, Hsiung CA, Kooperberg C, Haring B, Nassir R, Mathias R, Reiner A, Sankaran VG, Lowenstein CJ, Blackwell TW, Abecasis GR, Smith AV, Kang HM, Natarajan P, Jaiswal S, Bick A, Post WS, Scheet P, Auer P, Karantanos T, Battle A, Arvanitis M. Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations. Nat Commun. 2025 Oct 16;16(1):9194.

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

October 16, 2025

Volume

16

Issue

1

Start / End Page

9194

Location

England

Related Subject Headings

  • Point Mutation
  • Humans
  • Germ-Line Mutation
  • Genomics
  • Genome-Wide Association Study
  • Clonal Hematopoiesis